![](/wp-content/uploads/2023/11/Screenshot-2023-11-06-at-10.33.25-AM.png)
$599
Novo London Q3 ’23 Earnings; Terns Doses First Patient in Ph1 Obesity Trial; Ionis, Regeneron, and Dario Q3 ’23 Earnings
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Terns, Ionis, Regeneron, and Dario. Below, FENIX provides highlights and insights into the respective news items.